Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 1
1983 1
1989 1
1992 1
1993 14
1994 2
1995 6
1996 6
1997 8
1998 3
1999 5
2000 31
2001 47
2002 64
2003 115
2004 108
2005 124
2006 142
2007 200
2008 215
2009 213
2010 207
2011 234
2012 262
2013 283
2014 269
2015 310
2016 341
2017 369
2018 380
2019 395
2020 442
2021 500
2022 473
2023 451
2024 177

Text availability

Article attribute

Article type

Publication date

Search Results

5,621 results

Results by year

Filters applied: . Clear all
Page 1
Levetiracetam.
Howard P, Remi J, Remi C, Charlesworth S, Whalley H, Bhatia R, Hitchens M, Mihalyo M, Wilcock A. Howard P, et al. J Pain Symptom Manage. 2018 Oct;56(4):645-649. doi: 10.1016/j.jpainsymman.2018.07.012. Epub 2018 Jul 21. J Pain Symptom Manage. 2018. PMID: 30036676 Free article. Review.
Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis.
Fang T, Valdes E, Frontera JA. Fang T, et al. Neurocrit Care. 2022 Feb;36(1):248-258. doi: 10.1007/s12028-021-01296-z. Epub 2021 Jul 20. Neurocrit Care. 2022. PMID: 34286461
The coprimary meta-analyses examined first seizure events in (1) levetiracetam versus no antiseizure medication and (2) levetiracetam versus other antiseizure medications in all ICH, TBI, SAH, and supratentorial neurosurgery populations. ...Levetiracetam may …
The coprimary meta-analyses examined first seizure events in (1) levetiracetam versus no antiseizure medication and (2) levetirace …
Levetiracetam-associated pancytopenia.
Unkun R, Kizilkilic EK, Delil S, Kemerdere R, Ozkara C. Unkun R, et al. Acta Neurol Belg. 2023 Aug;123(4):1625-1626. doi: 10.1007/s13760-022-02138-1. Epub 2022 Nov 7. Acta Neurol Belg. 2023. PMID: 36344882 No abstract available.
Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy.
Cerulli Irelli E, Cocchi E, Morano A, Gesche J, Caraballo RH, Lattanzi S, Strigaro G, Catania C, Ferlazzo E, Pascarella A, Casciato S, Quarato P, Pizzanelli C, Pulitano P, Giuliano L, Viola V, Mostacci B, Fortunato F, Marini C, Di Gennaro G, Gambardella A, Labate A, Operto FF, Giallonardo AT, Baykan B, Beier CP, Di Bonaventura C; Women With Epilepsy Treatment Options and Research (WETOR) Study Group. Cerulli Irelli E, et al. JAMA Neurol. 2023 Nov 1;80(11):1174-1181. doi: 10.1001/jamaneurol.2023.3400. JAMA Neurol. 2023. PMID: 37782485
EXPOSURES: Levetiracetam or lamotrigine as initial monotherapy. MAIN OUTCOMES AND MEASURES: Inverse probability of treatment weighting (IPTW)-adjusted Cox proportional hazards regression was performed to compare treatment failure (TF) among patients who received levetir …
EXPOSURES: Levetiracetam or lamotrigine as initial monotherapy. MAIN OUTCOMES AND MEASURES: Inverse probability of treatment weightin …
Levetiracetam.
Alrabiah H. Alrabiah H. Profiles Drug Subst Excip Relat Methodol. 2019;44:167-204. doi: 10.1016/bs.podrm.2019.02.003. Epub 2019 Mar 25. Profiles Drug Subst Excip Relat Methodol. 2019. PMID: 31029217
A comprehensive profile of levetiracetam is presented in this chapter which includes its description, formula, elemental analysis, appearance, uses and applications. ...
A comprehensive profile of levetiracetam is presented in this chapter which includes its description, formula, elemental analysis, ap …
Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
Steinhoff BJ, Klein P, Klitgaard H, Laloyaux C, Moseley BD, Ricchetti-Masterson K, Rosenow F, Sirven JI, Smith B, Stern JM, Toledo M, Zipfel PA, Villanueva V. Steinhoff BJ, et al. Epilepsy Behav. 2021 May;118:107939. doi: 10.1016/j.yebeh.2021.107939. Epub 2021 Apr 8. Epilepsy Behav. 2021. PMID: 33839453 Free article. Review.
PURPOSE: To understand the currently available post-marketing real-world evidence of the incidences of and discontinuations due to the BAEs of irritability, anger, and aggression in people with epilepsy (PWE) treated with the anti-seizure medications (ASMs) brivaracetam (BRV), …
PURPOSE: To understand the currently available post-marketing real-world evidence of the incidences of and discontinuations due to the BAEs …
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1375-1386. doi: 10.1016/S0140-6736(21)00246-4. Lancet. 2021. PMID: 33838758 Free PMC article. Clinical Trial.
Participants were randomly allocated (1:1) to receive either levetiracetam or valproate, using a minimisation programme with a random element utilising factors. ...For participants aged 12 years or older, the initial advised maintenance doses were 500 mg twice per day for …
Participants were randomly allocated (1:1) to receive either levetiracetam or valproate, using a minimisation programme with a random …
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016/S0140-6736(21)00247-6. Lancet. 2021. PMID: 33838757 Free PMC article. Clinical Trial.
SANAD II was designed to assess non-inferiority of both levetiracetam and zonisamide to lamotrigine for the primary outcome of time to 12-month remission. ...INTERPRETATION: These findings do not support the use of levetiracetam or zonisamide as first-line treatment …
SANAD II was designed to assess non-inferiority of both levetiracetam and zonisamide to lamotrigine for the primary outcome of time t …
Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.
Lyttle MD, Rainford NEA, Gamble C, Messahel S, Humphreys A, Hickey H, Woolfall K, Roper L, Noblet J, Lee ED, Potter S, Tate P, Iyer A, Evans V, Appleton RE; Paediatric Emergency Research in the United Kingdom & Ireland (PERUKI) collaborative. Lyttle MD, et al. Lancet. 2019 May 25;393(10186):2125-2134. doi: 10.1016/S0140-6736(19)30724-X. Epub 2019 Apr 17. Lancet. 2019. PMID: 31005385 Free PMC article. Clinical Trial.
BACKGROUND: Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the effi …
BACKGROUND: Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in …
Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal epilepsy: A systematic review and meta-analysis.
Kharel S, Ojha R, Khanal S. Kharel S, et al. Brain Behav. 2022 Nov;12(11):e2779. doi: 10.1002/brb3.2779. Epub 2022 Oct 2. Brain Behav. 2022. PMID: 36184821 Free PMC article. Review.
OBJECTIVE: To compare the efficacy and safety of Levetiracetam (LEV) and Oxcarbazepine (OXC) as monotherapy for the treatment of newly diagnosed focal epilepsy. ...
OBJECTIVE: To compare the efficacy and safety of Levetiracetam (LEV) and Oxcarbazepine (OXC) as monotherapy for the treatment of newl …
5,621 results

Searches related to "levetiracetam"